Osteopenia Completed Phase 3 Trials for Alendronic acid (DB00630)

Also known as: Osteopaenia / Bone loss

IndicationStatusPhase
DBCOND0015922 (Osteopenia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00330460A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.Treatment
NCT00463268Osteoporosis Prevention With Low Dose AlendronatePrevention